{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Bracket Global, LLC', 'San Francisco, CA 94133', '575 East Swedesford Road Endpoint', 'USA', '55 Francisco Street, Suite 200', 'Wayne, PA 19087 San Francisco, CA', '94133', 'ePRO, eCOA, and Scales Training', 'Bracket Global, LLC', 'USA', '575 East Swedesford Road, Suite 200', 'Wayne, PA 19087', 'ePRO, eCOA, and Scales Training', 'USA', 'Bracket Global, LLC', '575 East Swedesford Road, Suite 200', 'Wayne, PA 19087', 'USA', 'Bioanalytical Pharmacokineties', 'Evaluation Data Analysis', 'Information will be included in the Trial', 'Master File.', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', \"Sponsor's Authorized Representative:\", \"Sponsor's Authorized Representative:\", 'Update to', 'the', \"Sponsor's\", 'authorized', 'representati', 've. In', 'addition,', 'medical', 'director/me', 'For medical issues, contact the physician', 'For medical issues, contact the physician', 'dical', 'listed below:', 'listed below:', 'monitor', 'contacts', 'outside of', 'North', 'America', 'have been', 'included.', 'Administrat', 'ive changes', 'carried out', 'for clarity.', 'For operational issues, contact the', 'operational lead listed below:', '174']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'For protocol issues, contact the study', 'leaders listed below:', '175']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'For protocol issues, contact the study', 'leaderleaders listed below:', 'For operational issues, contact the', 'operational lead listed below:', 'CLINICAL STUDY PROTOCOL SYNOPSIS', 'Type of the Study Phase of Clinical', 'Type of the Study: Efficacy and Safety', 'Template', 'Development: Efficacy and Safety (Phase', '(Phase 2/3)', 'update.', '2/3)', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 3.1.2', 'Screening Period, 3.4 Safety Measures and Time Points, 3.13.1 Procedures for Screening and', 'Enrollment, 4.1 Patient Inclusion Criteria, 5.2 Restrictions, 7.1.2 Recording and Reporting Adverse', 'Events, 7.1.5 Serious Adverse Events, 11.3 Study Monitoring, 12.1 Informed Consent/Assent, 13.1', 'Data Collection, 13.3.2 Investigator Responsibilities)', 'After informed consent-(andwritten-/assent', 'After informed consent/assent, depending', 'Provisions', 'and/or co consent for patients 14 years of,', \"on the child's age, as appropriate, is\", 'on informed', \"depending on the child's age-and older, as\", 'obtained', 'consent/ass', 'appropriate), is obtained', 'ent have', 'been more', 'clearly', 'provided', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 3.1.2', 'Screening Period)', '176']\n\n###\n\n", "completion": "END"}